1506 ET - SIGA Technologies started working on its antiviral drug TPOXX nearly 20 years ago to help defend against a smallpox bioterrorism attack. But SIGA shares have more than doubled this year, driven by rising demand for TPOXX to treat monkeypox. But despite high interest from government health officials around the world, many countries are waiting to see if the epidemic continues to get worse before making large orders of the drug, SIGA CEO Phillip Gomez told Dow Jones in an interview. On Thursday, World Health Organization officials said at a press briefing that global monkeypox cases dropped 21% last week, and that there are signs of the epidemic slowing in Europe despite rising case counts in the US. SIGA shares are down 14%. (joseph.walker@wsj.com)
$(END)$ Dow Jones Newswires
August 25, 2022 15:06 ET (19:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Comments